Collegium Pharmaceutical, Inc. COLL Belbuca — 2027
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — 2027.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s belbuca — 2027?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — 2027 of $0 in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s belbuca — 2027 changed year-over-year?
- Collegium Pharmaceutical, Inc.'s belbuca — 2027 decreased by 100.0% year-over-year, from $75.39M to $0.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — 2027?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — 2027 has grown at a -0.2% compound annual growth rate (CAGR), from $303.67M to $301.57M.
- What does belbuca — 2027 mean?
- The projected amortization expense specifically allocated to Belbuca-related intangible assets for the fiscal year 2027. This forward-looking metric assists in modeling long-term earnings and assessing the remaining useful life of the asset.